Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar control in patients with type 2 diabetes when added to a sulfonylurea, glimepiride (dual combination therapy), or when added to a sulfonylurea and metformin (triple combination therapy). Additional data were presented at the meeting regarding the efficacy and safety of JANUVIA.

JANUVIA is a selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances a natural body system, called the incretin system, which helps to regulate glucose by affecting the beta cells and alpha cells in the pancreas. JANUVIA is the first and only DPP-4 inhibitor to be approved and marketed in the United States for patients with type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus. JANUVIA is also indicated to improve glycemic control, in combination with metformin or a thiazolidinedione (TZD), in patients with type 2 diabetes when the single agent alone plus diet and exercise do not provide adequate glycemic control. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... Germany , Aug. 21, 2014  IBM (NYSE: ... Elektronen-Synchrotron ( DESY ), a leading national research center ... management and storage of massive volumes of x-ray data. ... based on IBM software defined technology can handle more ... performance and help scientists worldwide gain faster insights into ...
(Date:8/21/2014)...  Seventy-one percent of Americans believe the abuse of strong ... health and safety issue in the United States ... by Repass & Partners, a Cincinnati ... severity of the prescription medication abuse problem and the need ... health situation facing our country," Rex Repass , CEO ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... Fla., Dec. 5, 2011 Hybrid Fuels, Inc., (Pink ... of its main business activities and new strategic goals.  ... a nutraceutical/pharmaceutical business venture that will focus on providing ... normally be treated or addressed with pharmaceutical drugs that ...
... Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical ... inflammation and autoimmune disorders, today announced Dr. Debra Odink ... Officer and Senior Vice President. "Over ... scientific leadership has been critical to the success of ...
Cached Medicine Technology:Hybrid Fuels, Inc. Announces New Business Strategy 2Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer 2
(Date:8/22/2014)... 22, 2014 Beat Eczema , ... can use natural methods to completely cure the eczema ... attention of Shane Michaels, prompting an investigative review. ... the skin, it can still be extremely debilitating and ... “The intense itching and pain that it causes on ...
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... August 22, 2014 Testosterone treatment ... in U.S. courts on behalf of men who ... use of prescription low testosterone therapies, Bernstein Liebhard ... claim was filed against Pfizer Inc. on July ... life-threatening heart issues due to his use of ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... to Assure ... POWELL, Ohio, June 2 Click4Care, Inc., a ... payers,providers and patients, today announced that Cariten Healthcare, one ... subsidiary of,Covenant Health, has selected ThinkHealth for its medical ...
... Awarded Seven Gold Healthcare Advertising Marketing Awards, ... record number of over 4,400,entries, the 25th ... awards to Publicis Indianapolis and St. Vincent ... television), and marketing,work. Additionally, both entities won ...
... In a multi-site study, Oregon Health & Science University ... also known as MDX-010, works to stimulate the body,s own ... to be effective in study participants with a serious type ... and was resistant to hormonal treatment and, in some cases, ...
... (BioMedical Enterprises, Inc.),a privately held medical device company and ... launch of the OSSAnchor(TM),Grip, a nitinol implant designed to ... the first in the family of OSSAnchor(TM) nitinol soft,tissue ... Grip is a,nitinol implant with aggressive barbs on the ...
... Care Association Raising Profile of Key Issue Impacting,Texas Seniors, ... June 2 With just more than,five months until ... by Baselice Associates finds 57% of voters less likely ... she opposed increasing the amount,the state pays nursing homes ...
... Entitled, ,Ingenuity at Work, Discusses Abbott,s, Contributions to ... ABBOTT PARK, Ill., June 2 Abbott (NYSE: ... Report, "Ingenuity at Work,",which is available online at ... access to care, innovation, science,education and the environment., ...
Cached Medicine News:Health News:Click4Care Signs Award-Winning 500,000-Member Health Plan 2Health News:Publicis Indianapolis and St. Vincent Hospital Win the Gold 2Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 2Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 3Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor 2Health News:Texas Eldercare Poll: 57 Percent Less Likely to Back Local Legislator if They Oppose Medicaid Rate Boost 2Health News:Texas Eldercare Poll: 57 Percent Less Likely to Back Local Legislator if They Oppose Medicaid Rate Boost 3Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 2Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 3
The rectangular large-field lens of the 2631 are ideal for reading and writing....
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
Thinprofile design eyelid implants....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Medicine Products: